Calcium Channel Blocker Market Trends, Share, Growth, Value, Analysis | Business Review, Key Findings, Developing Technologies
Luton, Bedfordshire, United Kingdom, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has completed and published the final copy of the detailed research report on the Calcium Channel Blocker Market.
The Calcium Channel Blocker Market is projected to register a CAGR of 5.3 % during the forecast period, to reach a valuation of USD 20.15 Billion by 2029.
There are short-acting and long-acting calcium channel blockers. Compared to long acting calcium channel blockers, short acting medications have a quicker reaction. The calcium channel blocker drug class includes Amlodipine (Norvasc), Diltiazem (Cardizem, Tiazac, and others), Felodipine, Isradipine, and Nicardipine. These medications are used to treat coronary artery disease, angina, irregular heartbeats (arrhythmia), and blood vessel conditions like Raynaud's disease.
Calcium channel blockers, also known as calcium antagonists, are prescription medications that are frequently used to treat blood diseases, particularly circulatory illnesses, as well as cardiac conditions including excessive blood pressure, angina, and arrhythmias. These inhibitors function by obstructing voltage-gated calcium channels, which in turn limits calcium entry into cardiac and smooth muscle cells.
Get Access to sample Report Pages: -
https://www.pharmaresearchconsulting.com/reports/calcium-channel-blocker-market-growth-trends-and-forecast-2022-2029-by-drug-class-dihydropyridine-benzothizepine-phenylalkylamine-distribution-channel-hospital-pharmacies-retail-pharmacies-others-and-by-regions/inquiry
Calcium Channel Blocker Market: Opportunities
Increased Government Initiatives and Clinical Studies
Growing public awareness of channel blockers and research projects being undertaken by public and private organisations to better understand these blockers are predicted to propel industry expansion.
Demand for Retail Pharmacies is Growing
Opportunities for market expansion are created by the increase in calcium channel blockers being prescribed by retail pharmacies and the rise in the number of retail pharmacies in developed nations. Additionally, because retail pharmacies are more convenient for customers to reach, patients prefer them for medicine purchases.
Calcium Channel Blocker Market: Recent Development
The American Food and Drug Administration (FDA) granted provisional permission in May 2022 for Zydus Worldwide DMCC's subsidiary to commercialise Selexipag tablets for the treatment of pulmonary arterial hypertension (PAH) in adults.
The FDA approved Norliqva (amlodipine) oral solution in February 2022 to treat hypertension in adults and children aged 6 and older, as well as to prevent coronary artery disease.
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Drug Class, Distribution Channel, Region
North America; Europe; China; Asia; Pacific; Central & South America; MEA
U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Poland; Spain; India; Japan; Thailand; Malaysia; Indonesia; Vietnam; Singapore; Philippines; Brazil; Argentina; Saudi Arabia; UAE; Oman
Pfizer Inc, Alvogen, AstraZeneca, Abbvie Inc, Exela, Pharma Sciences, LLC, Bausch Health Company Inc., GlaxoSmithKline LLC, Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, Arbor Pharmaceuticals LLC, Others.
Calcium Channel Blocker Market Key Players
Calcium Channel Blocker Market Major Key Players include: - Pfizer Inc, Alvogen, AstraZeneca, Abbvie Inc, Exela, Pharma Sciences, LLC, Bausch Health Company Inc., GlaxoSmithKline LLC, Silvergate Pharmaceuticals Inc., Novartis AG, Covis Pharma BV, Arbor Pharmaceuticals LLC, Others.
Browse Complete Premium Report for Calcium Channel Blocker Market: https://www.pharmaresearchconsulting.com/reports/calcium-channel-blocker-market-growth-trends-and-forecast-2022-2029-by-drug-class-dihydropyridine-benzothizepine-phenylalkylamine-distribution-channel-hospital-pharmacies-retail-pharmacies-others-and-by-regions
Global Calcium Channel Blocker Market Dynamics
The market for calcium channel blockers is anticipated to expand quickly due to the rise in heart diseases. Obesity, an unhealthy lifestyle, junk food, and overeating are just a few of the factors contributing to the rise in cardiovascular disease (CVD), artery blockage, arrhythmias, and circulatory disorders.
The leading cause of death nationwide in 2017 was coronary heart disease, which claimed over 365,914 lives. Due to the increasing prevalence of cardiovascular illness worldwide, industry companies are investing enormous sums of money to create novel therapies and remain competitive. Additionally, pharmaceutical industry firms are concentrating on developing novel medication combinations to increase accuracy while reducing drug or medicine intake.
Pharmaceuticals like Ecosprin AV 75 pill, for example, combine two medications and are intended to prevent heart attack and stroke. This pill lowers levels of LDL, or "bad," cholesterol, including triglycerides, and boosts levels of HDL, or "good," cholesterol, in the body while also preventing blood clots from forming. Hence amalgamation of medicines by the market players is likely to boost the growth of the market.
Increase in Cardiovascular Diseases as Drivers
The WHO estimates that between 60% and 85% of people lead sedentary lives. Only one out of every four Americans fulfils the recommended levels of physical activity, according to the CDC, who estimates that 31 million individuals over the age of 50 lead sedentary lifestyles. This accelerates market expansion.
Oral medications are predicted to accelerate market expansion. Given that the majority of medications are accessible in capsule and tablet form and that this is a highly practical mode of administration, the category is anticipated to accelerate the worldwide market.
The expansion of the worldwide calcium channel blocker market over the forecast period may be restrained by a shortage of competent employees who are unable to treat patients with these medications.
The high cost of these agents undoubtedly inhibits market expansion.
Calcium Channel Blocker Market: Segmentation
By Drug Class, it is segmented into
By Distribution Channel it is segmented into
Calcium Channel Blocker Market: Regional Analysis
Due to the high incidence of poison cases and increase in research and development for antidotes, North America has seen good growth for the global calcium channel blocker market over the anticipated period. Due to its expanding healthcare infrastructure, substantial number of generic manufacturers, growing number of government initiatives, and specialised communities, Asia-Pacific dominates the industry.
COVID-19 Impact on Global Calcium Channel Blocker Market
Given the current situation, COVID-19 has left a historically severe worldwide public health crisis that has affected almost every industry, and its long-term effects are anticipated to have an impact on industry growth throughout the course of the projected period. Clinical trial delays and the transition of healthcare infrastructure to manage COVID-19 have resulted in the termination of medication launches.
Due to the demand for a COVID-19 vaccine and treatment medications in the post-pandemic era, it is anticipated that the biotechnology and pharmaceutical sectors would see tremendous growth in the coming years. As a result, this will have a big effect on calcium channel blocker sales.
Browse More Pharmaceutical Market Reports:
Hard capsules are dosage forms that can be solid or semi-solid and can include liquid, gaseous, powdered, or pasty materials within. These tablets are made of cellulose derivatives, a protein called gelatin, and fat-rich ingredients like cocoa butter.
https://www.pharmaresearchconsulting.com/reports/hard-capsules-market-global-growth-trends-and-forecast-2022-2029-by-type-gelatin-based-hard-capsule-vegetarian-based-hard-capsule-application-oral-cosmetic-clinical-research-and-by-regions
The sodium chloride injection market has seen a significant alteration throughout the predicted time frame. The increasing middle class, consumer spending, and demand for health care are the main factors driving the market for sodium chloride injection.
https://www.pharmaresearchconsulting.com/reports/sodium-chloride-injection-market-growth-trends-and-forecast-2022-by-type-flexible-bag-plastic-bottles-glass-bottles-therapeutic-application-dehydration-generalized-weakness-end-user-hospitals-clinics-and-by-regions
Hemostasis And Tissue Sealing Agents Market
Hemostasis and Tissue Sealing Agents Market will register a CAGR of 8.5 % in revenue, and the global market size will reach USD 10 Billion by 2029.
https://www.pharmaresearchconsulting.com/reports/hemostasis-and-tissue-sealing-agents-market-global-growth-trends-and-forecast-2022-2029-by-product-topical-hemostat-adhesives-tissue-sealant-by-regions
UBS's Colin Bristow raised his rating on the stock to Buy from Neutral, saying Well Street's expectations for sales of Mounjaro are too low.
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
OpSens Inc. ("OpSens" or the "Company") (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that Dr. Philippe Genereux, Director of the Structural Heart Program at Morristown Medical Center in New Jersey, and his team, performed the first use of SavvyWire in a transcatheter aortic valve replacement (TAVR) procedure in the United States.
Around one in five vaccinated Britons with Omicron or Delta strain experienced diarrhoea as a symptom
A big question with the new COVID-19 vaccine: Can you mix brands? Here is what experts say
Eli Lilly's blockbuster potential diabetes drug Mounjaro is "de-risked and transformative," an analyst said Thursday as he updated LLY stock.
Here's my pick for the best stock to buy right now with recession fears rising. Vertex Pharmaceuticals (NASDAQ: VRTX) has soared close to 30%, absolutely trouncing the S&P 500. How has Vertex seemingly defied gravity?
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.
The 'wrongful death' suit could usher in a new threat for abortion providers and women nationwide
Eli Lilly is the IBD Stock Of The Day as investors watch the company's obesity and Alzheimer's drugs, which could help shares skyrocket.
From biotech to managed care, companies are tackling new challenges in science and business. Our healthcare roundtable experts pick 12 stocks that could win.
Lung disease can manifest in a number of ways. Mr. Suphachai Praserdumrongchai/iStock via Getty Images Plus“I just can’t do what I used to anymore.” As pulmonologists and critical care doctors treating patients with lung disease, we have heard many of our patients recovering from COVID-19 tell us this even months after their initial diagnosis. Though they may have survived the most life-threatening phase of their illness, they have yet to return to their pre-COVID-19 baseline, struggling with ac
The social media giant’s head of community operations apologised at the inquest into the teenager’s death on Thursday.
Meghan McCain called the Georgia gubernatorial candidate "sick" for saying "there is no such thing as a heartbeat at six weeks" of pregnancy.
If you feel like you keep getting every cold going around, you might not be imagining it. Experts share tips to prevent colds and stay healthy this winter.
Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing.
After an Indiana judge on Thursday blocked the state's abortion ban from being enforced, phones starting ringing across Indiana abortion clinics, which are preparing to resume the procedure a week after the ban had gone into effect. “People are getting the word that abortion is now legal again, and people are ready to get their health care that they deserve and that they desire,” Dr. Katie McHugh, an abortion provider at Women's Med in Indianapolis, told The Associated Press. Owen County Judge Kelsey Hanlon issued a preliminary injunction against the ban, putting the new law on hold as abortion clinic operators argue in a lawsuit that it violates the state constitution.
Terminally-ill cancer patients have seen their tumours completely eradicated or shrunk after being treated with a genetically-engineered version of the herpes virus.
The latest data from the RELIEF Study suggests a lower rate of hospitalizations from serious diabetes-related events with Abbott's (ABT) FreeStyle Libre system.
Those hospitalized with COVID were 45% more likely to have heart failure after discharge than those hospitalized for another reason, the study found.